AcelRx Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Redwood City CA United States (2005)
Status: Acquired by Juventas Therapeutics, Inc. (2009)

Organization Overview

First Clinical Trial
2008
NCT00612534
First Marketed Drug
2018
sufentanil
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ACELRX PHARMS | Chief Medical Officer, AcelRx Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (1)

sufentanil (2018)

Drugs in Phase 3 Trials (2)

morphine (1 trial)

sufentanil (17 trials)

Drugs in Phase 2 Trials (1)

triazolam (halcion) (1 trial)

Drugs in Phase 1 Trials (1)

ketoconazole (nizoral) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 3)

Breakthrough Pain (Phase 2)

Pain, Postoperative (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 4